TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
- PMID: 36246941
- PMCID: PMC9559073
- DOI: 10.1016/j.xops.2021.100076
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
Abstract
Purpose: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the first bispecific antibody for intraocular use, which independently binds and neutralizes both angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A) versus aflibercept in patients with neovascular age-related macular degeneration (nAMD).
Design: Identical, global, double-masked, randomized, controlled, phase 3 clinical trials.
Participants: Adults with treatment-naïve nAMD.
Methods: These trials were designed to evaluate patients randomized to receive faricimab 6.0 mg up to every 16 weeks after 4 initial every-4-week doses or aflibercept 2.0 mg every 8 weeks after 3 initial every-4-week doses. The initial doses in the faricimab arm were followed by individualized fixed treatment intervals up to week 60, based on disease activity assessment at weeks 20 and 24, guided by central subfield thickness, best-corrected visual acuity (BCVA), and investigator assessment. The primary efficacy end point was BCVA change from baseline averaged over weeks 40, 44, and 48. Secondary end points included the proportion of patients receiving every-8-week, every-12-week, and every-16-week faricimab and anatomic outcomes. Safety outcomes included incidence and severity of ocular and nonocular adverse events. From week 60, faricimab-treated patients followed a personalized treatment interval (PTI), a novel protocol-driven treat-and-extend regimen with interval adjustment from every 8 weeks to every 16 weeks based on individualized treatment response measured by anatomic criteria, functional criteria, and investigator assessment of patients' disease activity.
Main outcome measures: Rationale for trial design and PTI approach.
Results: The TENAYA and LUCERNE trials were the first registrational trials in nAMD to test fixed dosing regimens up to every 16 weeks based on patients' disease activity in year 1 and incorporate a PTI paradigm during year 2. The PTI approach was designed to tailor treatment intervals to individual patient needs, to reflect clinical practice treatment practice, and to reduce treatment burden.
Conclusions: The innovative trial design rationale for the TENAYA and LUCERNE trials included maximizing the benefits of angiopoietin-2 blockade through dosing up to every 16 weeks and PTI regimens based on patients' disease activity while fulfilling health authority requirements for potential registrational efforts.
Keywords: Anti-VEGF therapy; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CRC, central reading center; CST, central subfield thickness; FFA, fundus fluorescein angiography; Faricimab; Neovascular age-related macular degeneration; PTI, personalized treatment interval; Personalized treatment interval; T&E, treat-and-extend; VEGF, vascular endothelial growth factor; nAMD, neovascular age-related macular degeneration.
© 2021 by the American Academy of Ophthalmology.
Figures
Similar articles
-
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Clinical Trial.
-
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar. Ophthalmol Sci. 2021. PMID: 36246184 Free PMC article.
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
-
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.Graefes Arch Clin Exp Ophthalmol. 2024 Jun 7. doi: 10.1007/s00417-024-06531-9. Online ahead of print. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38847896 Review.
-
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.Int J Retina Vitreous. 2024 Jan 17;10(1):5. doi: 10.1186/s40942-024-00525-9. Int J Retina Vitreous. 2024. PMID: 38233896 Free PMC article. Review.
Cited by
-
Faricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes.Ophthalmol Ther. 2024 Aug 9. doi: 10.1007/s40123-024-01005-x. Online ahead of print. Ophthalmol Ther. 2024. PMID: 39122857
-
Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD.J Clin Med. 2024 Jul 19;13(14):4227. doi: 10.3390/jcm13144227. J Clin Med. 2024. PMID: 39064267 Free PMC article. Review.
-
Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents.Int J Mol Sci. 2024 Apr 17;25(8):4433. doi: 10.3390/ijms25084433. Int J Mol Sci. 2024. PMID: 38674018 Free PMC article. Review.
-
Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration.J Clin Med. 2024 Apr 21;13(8):2417. doi: 10.3390/jcm13082417. J Clin Med. 2024. PMID: 38673690 Free PMC article.
-
Quantifying Fluid and Function in Suboptimal Responders Switched From an Anti-vascular Endothelial Growth Factor (VEGF) to Faricimab.Cureus. 2024 Mar 21;16(3):e56652. doi: 10.7759/cureus.56652. eCollection 2024 Mar. Cureus. 2024. PMID: 38516283 Free PMC article.
References
-
- Wong W.L., Su X., Li X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. - PubMed
-
- Brown D.M., Michels M., Kaiser P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5. - PubMed
-
- Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. - PubMed
-
- Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. - PubMed
Associated data
LinkOut - more resources
Full Text Sources